Guggenheim Downgrades Alumis to Neutral
Guggenheim analyst Yatin Suneja downgrades Alumis (NASDAQ:ALMS) from Buy to Neutral.
BenzingayesterdayALMS
Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37
Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:ALMS) with a Outperform and lowers the price target from $55 to $37.
Benzinga2 days agoALMS
Wells Fargo Maintains Overweight on Alumis, Lowers Price Target to $25
Wells Fargo analyst Derek Archila maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the price target from $51 to $25.
Benzinga2 days agoALMS
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
Benzinga2 days agoALMS
This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Analysts upgraded Alumis, Sirius XM, OGE Energy, revising their price targets and outlooks.
Benzinga2 days agoALMS
Morgan Stanley Maintains Overweight on Alumis, Lowers Price Target to $29
Morgan Stanley analyst Terence Flynn maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the price target from $39 to $29.
Benzinga2 days agoALMS
HC Wainwright & Co. Upgrades Alumis to Buy, Lowers Price Target to $15
HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Alumis (NASDAQ:ALMS) from Neutral to Buy and lowers the price target from $25 to $15.
Benzinga2 days agoALMS
Here are the top movers in Tuesday's session.
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
ChartMill3 days agoALMS
HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Neutral and maintains $25 price target.
Benzinga21 days agoALMS
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO – – Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in moderate-to-severe plaque psoriasis (PsO) in Q4 2026 – – Potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE anticipated in Q3 2026 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma
Yahoo21 days agoALMS
Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate
Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.71) by 56.34 percent. This is a 12.6 percent increase over losses of $(1.27) per share from the same
Benzinga22 days agoALMS
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Yahoo24 days agoALMS
Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates
Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with FDA.
Benzinga24 days agoALMS
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
– ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment – – Favorable long-term safety and tolerability profile remained consistent with previously reported data – – On track to submit a New Drug Application to FDA in 4Q 2026 – SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with i
Yahoo24 days agoALMS
Alumis Reports Topline Results From Ongoing ONWARD3 Long-Term Extension Study Showing 54% Of Patients Reached Complete Skin Clearance After 48 Weeks Of Continuous Envudeucitinib Treatment
– Favorable long-term safety and tolerability profile remained consistent with previously reported data –– On track to submit a New Drug Application to FDA in 4Q 2026 –SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE
Benzinga25 days agoALMS